Lyophilization cycle development for a high-concentration monoclonal antibody formulation lacking a crystalline bulking agent.

An efficient freeze-dry cycle was developed for a high concentration monoclonal antibody formulation lacking a crystalline bulking agent. The formulation, at multiple protein concentrations, was characterized using differential scanning calorimetry (DSC) and freeze-dry microscopy. At low protein concentrations the glass transition temperature of the maximally freeze-concentrated solution (T(g)') determined by DSC was similar to the collapse temperature determined by freeze-dry microscopy. However, at higher protein concentrations, the difference between collapse temperature and T(g)' became progressively larger. The difference between the onset temperature for collapse and the complete collapse temperature also became progressively larger as protein concentration increased. JMP Design of Experiment studies were used to assess the effect of freezing rate, primary drying shelf temperature, and chamber pressure on primary drying product temperature, length of primary drying, and product quality attributes. Primary drying was shortened significantly by adjusting to conditions where the product temperature substantially exceeded T(g)' without any apparent detrimental effect to the product.

[1]  Xiaolin Tang,et al.  Design of Freeze-Drying Processes for Pharmaceuticals: Practical Advice , 2004, Pharmaceutical Research.

[2]  E. Goormaghtigh,et al.  Determination of soluble and membrane protein structure by Fourier transform infrared spectroscopy. II. Experimental aspects, side chain structure, and H/D exchange. , 1994, Sub-cellular biochemistry.

[3]  Steven L Nail,et al.  Fundamentals of freeze-drying. , 2002, Pharmaceutical biotechnology.

[4]  J. Carpenter,et al.  Application of infrared spectroscopy to development of stable lyophilized protein formulations. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  C. Bindschaedler LYOPHILIZATION PROCESS VALIDATION , 1999 .

[6]  J. Carpenter,et al.  Annealing to optimize the primary drying rate, reduce freezing-induced drying rate heterogeneity, and determine T(g)' in pharmaceutical lyophilization. , 2001, Journal of pharmaceutical sciences.

[7]  Michael J. Pikal,et al.  The secondary drying stage of freeze drying: drying kinetics as a function of temperature and chamber pressure☆ , 1990 .

[8]  T. Spitznagel,et al.  Characterization of the sucrose/glycine/water system by differential scanning calorimetry and freeze-drying microscopy. , 1998, Pharmaceutical development and technology.

[9]  Michael J. Pikal,et al.  Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice , 1997, Pharmaceutical Research.

[10]  Xinghang Ma,et al.  Characterization of Murine Monoclonal Antibody to Tumor Necrosis Factor (TNF-MAb) Formulation for Freeze-Drying Cycle Development , 2004, Pharmaceutical Research.

[11]  W. Wang,et al.  Lyophilization and development of solid protein pharmaceuticals. , 2000, International journal of pharmaceutics.

[12]  N. A. Williams,et al.  The lyophilization of pharmaceuticals: a literature review. , 1984, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.